United States Liquid Biopsy Market was valued at US$ 3,405.8 million in 2022 and is projected to surpass a market valuation of US$ 10,798 million by 2031 at a CAGR of 13.68% during the forecast period 2023–2031.
The US liquid biopsy market has experienced remarkable growth in recent years, with technological advancements, the growing prevalence of cancer and chronic diseases driving this surge in interest and application. As of 2023, the US market has become highly competitive with several established players and emerging startups vie for market share. Guardant Health, a leading player in the market, accounted for a significant market share in 2022. However, the main competitor to liquid biopsies, traditional tissue biopsies, still account for approximately 70% of all biopsies performed in the US. The remaining 30% is now represented by liquid biopsies due to their non-invasive nature, faster results, and ability to provide more comprehensive insights into tumor heterogeneity.
As per our study, oncologists, pathologists, and surgeons have remain the key end users and have been rapidly adopting liquid biopsy technology. Approximately 55% of oncologists in a recent survey expressed their intention to increase their use of liquid biopsies within the next year. Furthermore, patient demand for less invasive diagnostic options is on the rise, with an estimated 30% increase in patient inquiries about liquid biopsies in the past year alone. Furthermore, government regulation and policies have also played a role in shaping the liquid biopsy market. The FDA has approved 12 liquid biopsy tests for various cancer types as of 2023, reflecting a growing acceptance of this technology in clinical practice. Additionally, the US government's $215 million investment in the Precision Medicine Initiative has further boosted the market.
Looking ahead, the liquid biopsy market is poised for continued growth. As liquid biopsies become more widely accepted and integrated into clinical practice, the market could witness a 20% increase in the number of tests performed annually. Moreover, as technological advancements lead to more accurate and cost-effective tests, liquid biopsies may eventually account for up to 50% of all biopsies performed.
To Get more Insights, Request A Free Sample
As the technology for liquid biopsy evolves, there is an explosion of data that needs to be interpreted accurately and efficiently. AI, with its advanced machine learning and deep learning capabilities, offers an efficient way to analyze complex and large datasets, which traditional data analysis methods might struggle to process. Among the factors contributing to this growth, the integration of AI has played a critical role. The application of AI in liquid biopsy analysis has grown at an impressive rate of approximately 28% annually over the past five years.
More number of end users in the US liquid biopsy market are making use of this technology as it significantly increases speed of data analysis. A 2022 study conducted by the University of California showed that an AI-powered algorithm could analyze liquid biopsy data in just 30 minutes, compared to the several hours required by conventional methods. Moreover, AI increases the accuracy of data interpretation. In a study published in the journal "Cancer Research" in 2022, an AI algorithm demonstrated an accuracy rate of 95% in identifying specific cancer mutations from liquid biopsy data. This is significantly higher than the 85% accuracy achieved by traditional data analysis methods. AI also enables the identification of patterns and correlations that might be missed by human analysts. In a study conducted by MIT in 2021, an AI algorithm identified previously unknown correlations between specific biomarkers in liquid biopsy data and the aggressiveness of certain types of cancer. Such insights can significantly improve the early diagnosis and treatment of cancer.
Despite the promise of AI in liquid biopsy analysis, there are challenges. One significant restraint facing the liquid biopsy market is the high cost of liquid biopsy tests. In 2022, the average cost of a liquid biopsy test was approximately $2,800, nearly four times higher than the average cost of a traditional tissue biopsy. This high cost has deterred many healthcare providers and patients from adopting liquid biopsies.
The high cost is primarily attributed to the technology used for liquid biopsies, such as next-generation sequencing (NGS) and digital PCR, is expensive. The integration of AI further adds to the cost, as it requires powerful computing systems and advanced algorithms. Apart from this, the lack of widespread reimbursement for liquid biopsy tests further exacerbates the issue. As of 2023, Medicare only covers a limited number of liquid biopsy tests, and private insurance coverage varies widely. As a result, the adoption of liquid biopsies has been limited to larger hospitals and research institutions, which have the resources to absorb the high costs. There are also some concerns about the validity of AI algorithms in the liquid biopsy market. While AI has shown promise in liquid biopsy analysis, there is still a need for extensive validation of AI algorithms through rigorous clinical studies. In a survey conducted by the American Association of Clinical Oncology in 2022, 61% of oncologists expressed concerns about the lack of validation of AI algorithms used in liquid biopsy analysis.
Liquid biopsies have primarily been used for cancer detection, monitoring, and treatment planning. However, recent research suggests that they could be used for other diseases, including cardiovascular diseases, neurodegenerative disorders, and infectious diseases. Several studies have shown that liquid biopsies can detect biomarkers associated with various non-cancerous conditions. For instance, a study published in the "Journal of the American College of Cardiology" in 2022 demonstrated that liquid biopsies could accurately detect specific RNA markers associated with heart failure. Another study published in "Nature Medicine" in 2021 showed that liquid biopsies could detect amyloid-beta, a protein associated with Alzheimer's disease. Furthermore, the COVID-19 pandemic has highlighted the potential of liquid biopsies for infectious disease diagnosis. Research conducted by the University of Washington in 2020 showed that liquid biopsies could detect viral RNA in blood samples from COVID-19 patients, offering a complementary diagnostic tool to the traditional nasal swab tests.
Expanding the applications of liquid biopsies beyond cancer diagnosis could significantly increase the market potential. With the US liquid biopsy market expected to reach $9.49 billion by 2030, broadening its applications could further accelerate this growth. It could open new revenue streams for liquid biopsy companies and potentially revolutionize the diagnosis and management of a wide range of diseases
In the US liquid biopsy market, technology is divided into Multi Gene Parallel Analysis (Next Generation Sequencing, NGS) and Single Gene Analysis (PCR Microarrays). Multi Gene Parallel Analysis, primarily conducted via NGS, has been dominating the market, accounting for more than 74% of market revenue in 2022. This trend is expected to continue, with a projected CAGR of 13.97% in the coming years. The dominance of NGS is attributed to its ability to analyze multiple genes simultaneously, providing a comprehensive view of genetic mutations in a single test. This makes it highly suitable for detecting and characterizing tumors, monitoring treatment responses, and identifying resistance mutations. NGS has also been instrumental in the development of targeted therapies and personalized treatment plans, further fueling its adoption.
Despite the dominance of NGS, single gene analysis, primarily through PCR Microarrays, continues to be an important technology in the liquid biopsy market. PCR Microarrays are preferred in certain clinical scenarios where the focus is on detecting specific gene mutations. They are also more cost-effective and time-efficient compared to NGS, making them an attractive option for routine testing and monitoring.
In the product segment, the liquid biopsy market is primarily divided into blood sample based and other types of samples (e.g., urine, cerebrospinal fluid). Blood samples have been the predominant choice for liquid biopsy, contributing more than 69% of market revenue in 2022. The blood sample segment is also expected to grow at a robust CAGR of 14.10% in the years to come. The preference for blood samples is primarily due to the ease and non-invasiveness of blood sample collection, making it a highly convenient and patient-friendly option. Blood samples also offer a rich source of biomarkers, including circulating nucleic acids, circulating tumor cells (CTCs), exosomes/microvesicles, and circulating proteins, allowing for comprehensive analysis and accurate diagnosis.
Other sample types, such as urine and cerebrospinal fluid, are gaining traction in specific clinical scenarios where blood samples may not provide adequate information. For instance, urine samples are being explored for diagnosing and monitoring bladder and kidney cancers, while cerebrospinal fluid is being investigated for brain and spinal cord tumors. However, these sample types currently represent a smaller portion of the market.
To Understand More About this Research: Request A Free Sample
The biomarker segment in the US liquid biopsy market comprises circulating nucleic acids, circulating tumor cells (CTCs), exosomes/microvesicles, and circulating proteins. Among these, circulating nucleic acids lead the market, contributing over 36% of market revenue in 2022, with a projected CAGR of 13.93% in the coming years. Circulating nucleic acids, which include cell-free DNA (cfDNA) and cell-free RNA (cfRNA), have emerged as valuable biomarkers for cancer diagnosis, prognosis, and monitoring. They offer insights into the genetic makeup of tumors and can be used to detect mutations associated with drug resistance. As a result, circulating nucleic acids have become an integral part of precision oncology, enabling personalized treatment strategies.
Circulating tumor cells (CTCs) are also gaining prominence in the liquid biopsy market due to their potential in identifying aggressive tumor subtypes, assessing prognosis, and predicting treatment response. Research is ongoing to develop CTC-based liquid biopsy tests for various cancer types, further enhancing their market potential. On the other hand, exosomes/microvesicles and circulating proteins represent other promising biomarker segments. Exosomes are cell-derived vesicles that contain RNA, DNA, and proteins, offering a holistic view of the tumor microenvironment. Circulating proteins, such as tumor-specific antigens, provide valuable information on tumor burden and can be used for early cancer detection. Both these segments are expected to grow in importance as research advances and their clinical applications become more evident.
By Technology
By Product
By Biomarker
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.
SPEAK TO AN ANALYST
.png)
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0823577 | Delivery: 2 to 4 Hours 
.svg)
